Two Sigma Advisers Reduces $8M in Ardelyx, Inc. ($ARDX)
Key Points
- Two Sigma Advisers changed its Ardelyx, Inc. ($ARDX) stake by 100.0% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $ARDX is Strong Buy and an average price target of $16.33.
- $ARDX last traded around $5.79.
Two Sigma Advisers reduced its position in Ardelyx, Inc. ($ARDX), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Ardelyx, Inc. after selling 1,348,700 shares during the quarter.
Ardelyx, Inc. ($ARDX) Stock
Ardelyx, Inc. Earnings
Analysts Set New Price Targets
About Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.